22 related articles for article (PubMed ID: 8694547)
1. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
Zhao X; Xu X; Zhang Q; Jia Z; Sun S; Zhang J; Wang B; Wang Z; Hu X
BMC Cancer; 2011 Sep; 11():403. PubMed ID: 21936956
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer.
Tamiya M; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Yasue T; Matsuura Y; Hirashima T; Kawase I
Med Oncol; 2012 Mar; 29(1):215-8. PubMed ID: 21258879
[TBL] [Abstract][Full Text] [Related]
3. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
[TBL] [Abstract][Full Text] [Related]
5. Serum ostase in the follow-up of breast cancer patients.
Marchei P; Santini D; Bianco V; Chiodini S; Reale MG; Simeoni F; Marchei GG; Vecchione A
Anticancer Res; 1995; 15(5B):2217-22. PubMed ID: 8572628
[TBL] [Abstract][Full Text] [Related]
6. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
Einarsson R; Lindman H; Bergh J
Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
[TBL] [Abstract][Full Text] [Related]
7. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
[TBL] [Abstract][Full Text] [Related]
8. [CA15-3].
Inaji H
Nihon Rinsho; 2005 Aug; 63 Suppl 8():651-3. PubMed ID: 16149603
[No Abstract] [Full Text] [Related]
9. Use of markers of bone turnover for monitoring bone metastases and the response to therapy.
Lipton A; Costa L; Ali S; Demers L
Semin Oncol; 2001 Aug; 28(4 Suppl 11):54-9. PubMed ID: 11544577
[TBL] [Abstract][Full Text] [Related]
10. [Pyridinoline, deoxypyridinoline].
Ishikawa T; Okazaki R
Nihon Rinsho; 2004 Dec; 62 Suppl 12():224-7. PubMed ID: 15658305
[No Abstract] [Full Text] [Related]
11. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma.
Massidda B; Ionta MT; Foddi MR; Mascia L; Bruder F; Aloi MB; Meleddu C; Giannoni MN
Anticancer Res; 1996; 16(4B):2221-3. PubMed ID: 8694547
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
